|
急性白血病患者凝血酶激活纤溶抑制物检测的临床意义 |
| |
【摘要】 目的 了解急性白血病（AL）病人凝血酶激活纤溶抑制物（TAFI）活性水平的变化。方法 应用发色底物法检测50例AL病人及30例正常人的TAFI活性水平，并进行统计学比较。结果 AL病人治疗前TAFI：A为2.55±0.84 μg/ml，较正常对照组的7.22±2.22 μg/ml显著降低（P＜0.01）。急性早幼粒细胞白血病（APL）病人TAFI：A为1.50±0.14 μg/ml显著低于其它类型AL（P＜0.05）。结论 AL病人凝血酶激活的纤溶抑制物（TAFI）活性降低，以APL病人表现更显著，但其可随病情好转而逐渐改善。
【关键词】 急性白血病； 凝血酶激活纤溶抑制物
The Clinical Study of Plasma ThrombinActivatable Fibrinolysis Inhibitor in Patients with Acute Leukemia
CHENG Peng，PENG Zhigang，LUO Jun，MA Jie，LUO Lin，LIN Faquan
（The First Affiliated Hospital of Nanning Medical University，Nanning， 530021， China）
Abstract： Objective To explore the significance in the clinical therapy of acute leukemia（AL）.Methods 50 AL patients were selected into the study.The levels of thrombinactivatable fibrinolysis inhibitor ：A were measured by chromogenic assay.Meanwhile，the AL patients were measured before and after therapy.Results Compared with normal group，plasma levels of thrombinactivatable fibrinolysis inhibitor：A were degraded before treatment in AL patients （P＜0.01）.Plasma levels of thrombinactivatable fibrinolysis inhibitor ：A in APL were lower than the other type of acute leukemia.Conclusion Fibrinolysis existed in AL patients and the decrease of antifibrinolysis maybe [1] [2] [3] [4] [5] [6] 下一页
上一个医学论文： 糖尿病性乳酸酸中毒
下一个医学论文： 凝血酶原复合物的临床应用
|
|
|
|
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文